NCT04972227View on ClinicalTrials.gov

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

April 18, 2022

Study Completion Date

April 18, 2022

Conditions
Schizophrenia
Interventions
DRUG

CY6463

oral tablets

DRUG

Placebo

oral tablets

Trial Locations (2)

90806

Collaborative Neuroscience Network, Long Beach

08053

Hassman Research Institute, Marlton

Sponsors
All Listed Sponsors
lead

Tisento Therapeutics

INDUSTRY

NCT04972227 - Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia | Biotech Hunter | Biotech Hunter